Oral administration of MA-2029, a novel selective and competitive motilin receptor antagonist, inhibits motilin-induced intestinal contractions and visceral pain in rabbits

European Journal of Pharmacology

Volumn 581, Issue 3, 2008, Pages 296-305

  Sudo, Hirokazu ^a   Yoshida, Shoshin ^a   Ozaki, Ken ichi ^a   Muramatsu, Hiroyasu ^a   Onoma, Mitsu ^a   Yogo, Kenji ^a   Kamei, Kenshi ^a   Cynshi, Osamu ^a   Kuromaru, Osamu ^a   Peeters, Theo L ^b   Takanashi, Hisanori ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Colonic motility; MA 2029; Motilin; Motilin receptor antagonist; Visceral pain

Indexed keywords

ACETYLCHOLINE; HORMONE RECEPTOR BLOCKING AGENT; MA 2029; MOTILIN; SUBSTANCE P; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN HEK293; COLOMBIA; COLON; COLON MOTILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INHIBITION; DUODENUM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE CONTRACTION; IRRITABLE COLON; LIGAND BINDING; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RADIOASSAY; VISCERAL PAIN;

ADMINISTRATION, ORAL; ANIMALS; BINDING, COMPETITIVE; CELL LINE; COLON; DOSE-RESPONSE RELATIONSHIP, DRUG; DUODENUM; GASTROINTESTINAL MOTILITY; HUMANS; MALE; MOTILIN; MUSCLE CONTRACTION; OLIGOPEPTIDES; PAIN; PAIN MEASUREMENT; RABBITS; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, NEUROPEPTIDE;

EID: 38949163313     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.11.049     Document Type: Article

References (38)

1. Adachi H., Toda N., Hayashi S., Noguchi M., Suzuki T., Torizuka K., Yajima H., and Koyama K. Mechanism of the excitatory action of motilin on isolated rabbit intestine. Gastroenterology 80 (1981) 783-788
2. Alcalde A.I., Plaza M.A., and Marco R. Study of the binding of motilin to the membranes of enterocytes from rabbit jejunum. Peptides 17 (1996) 1237-1241
3. Beavers M.P., Gunnet J.W., Hageman W., Miller W., Moore J.B., Zhou L., Chen R.H.K., Xiang A., Urbanski M., Combs D.W., Mayo K.H., and Demarest K.T. Discovery of the first non-peptide antagonist of the motilin receptor. Drug Des. Discov. 17 (2001) 243-251
4. Besterman H.S., Sarson D.L., Rambaud J.C., Stewart J.S., Guerin S., and Bloom S.R. Gut hormone responses in the irritable bowel syndrome. Digestion 21 (1981) 219-224
5. Brown J.C., Mutt V., and Dryburgh J.R. The further purification of motilin, a gastric motor activity stimulating polypeptide from the mucosa of the small intestine of hogs. Can. J. Physiol. Pharm. 49 (1971) 399-405
6. Depoortere I., Peeters T.L., and Vantrappen G. Motilin receptors of the rabbit colon. Peptides 12 (1991) 89-94
7. Faghih R., Nellans H.N., and Plattner J.J. Motilides and motilactides: design and development of motilin receptor agonists as a new class of gastrointestinal prokinetic drugs. Drugs Future 23 (1998) 861-872
8. Feighner S.D., Tan C.P., McKee K.K., Palyha O.C., Hreniuk D.L., Pong S.S., Austin C.P., Figueroa D., MacNeil D., Cascieri M.A., Nargund R., Bakshi R., Abramovitz M., Stocco R., Kargman S., O'neill G., Vander Ploeg L.H.T., Evans J., Patchett A.A., Smith G.R., and Howard A.D. Receptor for motilin identified in the human gastrointestinal system. Science 284 (1999) 2184-2188
9. Fukudo S., and Suzuki J. Colonic motility, autonomic function, and gastrointestinal hormones under psychological stress on irritable bowel syndrome. Tohoku J. Exp. Med. 151 (1987) 373-385
10. Haramura M., Okamachi A., Tsuzuki K., Yogo K., Ikuta M., Kozono T., Takanashi H., and Murayama E. Design and synthesis of N-terminal cyclic motilin partial peptides: a novel pure motilin antagonist. Chem. Pharm. Bull. (Tokyo) 49 (2001) 40-43
11. Itoh Z. Motilin and clinical application. Peptides 18 (1997) 593-608
12. Kamerling I.M.C., Van Haarst A.D., Burggraaf J., De Kam M., Biemond I., Jones R., Cohen A.F., and Masclee A.A. Exogenous motilin affects postprandial proximal gastric motor function and visceral sensation. Dig. Dis. Sci. 47 (2002) 1732-1736
13. Kamerling I.M.C., Van Haarst A.D., Burggraaf J., Schoemaker R.C., Biemond I., Heinzerling H., Jones R., Cohen A.F., and Masclee A.A. Motilin effects on the proximal stomach in patients with functional dyspepsia and healthy volunteers. Am. J. Physiol. 284 (2003) G776-G781
14. Kamerling I.M.C., van Haarst A.D., Burggraaf J., Schoemaker R.C., De Kam M.L., Heinzerling H., Cohen A.F., and Masclee A.A. Effects of a nonpeptide motilin receptor antagonist on proximal gastric motor function. Br. J. Clin. Pharmacol. 57 (2004) 393-401
15. 13-motilin) on gastrointestinal motility in the rabbit. Br. J. Pharmacol. 111 (1994) 288-294
16. Koga H., Takanashi H., Itoh Z., and Ōmura S. Design, SAR and pharmacology of GM-611, the first acid-stable nonpeptide motilin receptor agonist. Drugs Future 27 (2002) 255-272
17. Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., and Spiller R.C. Functional bowel disorders. Gastroenterology 130 (2006) 1480-1491
18. Marsault E., Hoveyda H.R., Peterson M.L., Saint-Louis C., Landry A., Vézina M., Ouellet L., Wang Z., Ramaseshan M., Beaubien S., Benakli K., Beauchemin S., Déziel R., Peeters T.L., and Fraser G.L. Discovery of a new class of macrocyclic antagonists to the human motilin receptor. J. Med. Chem. 49 (2006) 7190-7197
19. McCallum R.W., Cynshi O., and US Investigative Team. Efficacy of mitemcinal, a motilin agonist, on gastrointestinal symptoms in patients with symptoms suggesting diabetic gastropathy: a randomized multi-center placebo-controlled trial. Aliment. Pharmacol. Ther. 26 (2007) 107-116
20. McCallum R.W., Cynshi O., and US Investigative Team. Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis - a randomized, multicentre, placebo-controlled study. Aliment. Pharmacol. Ther. 26 (2007) 1121-1130
21. McIntosh C.H., and Brown J.C. Purification and chemical structure of porcine and canine motilins and evidence of motilin in other species. In: Motilin Z., and Itoh (Eds) (1990), Academic Press, San Diego, CA 13-30
22. Mertz H., Naliboff B., Munakata J., Niazi N., and Mayer E.A. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 109 (1995) 40-52
23. Naliboff B.D., Munakata J., Fullerton S., Gracely R.H., Kodner A., Harraf F., and Mayer E.A. Evidence for two distinct perceptual alterations in irritable bowel syndrome. Gut 41 (1997) 505-512
24. Ness T.J., and Gebhart G.F. Visceral pain: a review of experimental studies. Pain 41 (1990) 167-234
25. Ohe K., Sumii K., Sano K., Kishimoto S., and Miyoshi A. Serum motilin in gastrointestinal disease. Endocrinol. Jpn. 27 Suppl 1 (1980) 167-172
26. 1 receptor antagonists on the viscerosensory response caused by colorectal distension in rabbits. J. Pharmacol. Exp. Ther. 300 (2002) 925-931
27. Ōmura S., Tsuzuki K., Sunazuka T., Marui S., Toyoda H., Inatomi N., and Itoh Z. Macrolides with gastrointestinal motor stimulating activity. J. Med. Chem. 30 (1987) 1941-1943
28. Peeters T.L. Erythromycin and other macrolides as prokinetic agents. Gastroenterology 105 (1993) 1886-1899
29. Peeters T.L., Depoortere I., Macielag M.J., Dharanipragada R., Marvin M.S., Florance J.R., and Galdes A. The motilin antagonist ANQ-11125 blocks motilide-induced contractions in vitro in the rabbit. Biochem. Biophys. Res. Commun. 198 (1994) 411-416
30. Poitras P., Miller P., Gagnon D., and St-Pierre S. Motilin synthetic analogues and motilin receptor antagonists. Biochem. Biophys. Res. Commun. 205 (1994) 449-454
31. Preston D.M., Adrian T.E., Christofides N.D., Lennard-Jones J.E., and Bloom S.R. Positive correlation between symptoms and circulating motilin, pancreatic polypeptide and gastrin concentrations in functional bowel disorders. Gut 26 (1985) 1059-1064
32. Simrén M., Abrahamsson H., and Bjornsson E.S. An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome. Gut 48 (2001) 20-27
33. Simrén M., Bjornsson E.S., and Abrahamsson H. High interdigestive and postprandial motilin levels in patients with the irritable bowel syndrome. Neurogastroenterol. Motil. 17 (2005) 51-57
34. Sjölund K., Ekman R., Lindgren S., and Rehfeld J.F. Disturbed motilin and cholecystokinin release in the irritable bowel syndrome. Scand. J. Gastroenterol. 31 (1996) 1110-1114
35. Tack J., Piessevaux H., Coulie B., Caenepeel P., and Janssens J. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 115 (1998) 1346-1352
36. Talley N.J., Verlinden M., Snape W., Beker J.A., Ducrotte P., Dettmer A., Brinkhoff H., Eaker E., Ohning G., Miner P.B., Mathias J.R., Fumagalli I., Staessen D., and Mack R.J. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment. Pharmacol. Ther. 14 (2000) 1653-1661
37. Talley N.J., Verlinden M., Geenen D.J., Hogan R.B., Riff D., McCallum R.W., and Mack R.J. Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial. Gut 49 (2001) 395-401
38. Takanashi H., Yogo K., Ozaki K., Ikuta M., Akima M., Koga H., and Nabata H. GM-109: A novel, selective motilin receptor antagonist in the smooth muscle of the rabbit small intestine. J. Pharmacol. Exp. Ther. 273 (1995) 624-628